Avania Acquires MAXIS

Avania has acquired MAXIS, a medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management.

Neither company disclosed the transaction’s financial terms.  
 
“This acquisition strengthens our position as a medtech focused CRO, advancing medical technologies from ideation to commercialization, providing a range of highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs,” Avania President/CEO Sapna Hornyak said. “The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow.”
 
The combined organization now offers high-touch strategic and operational expertise. MAXIS clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the United States, Europe, and Australia. Additionally, Avania brings enhanced services to the combined companies including biostatistics, data analytics, and medical writing.
 
“MAXIS’ commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources,” MAXIS Medical President Kathleen Marshall stated. “Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”
 
Avania customers will benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in-vitro diagnostics, artificial intelligence/machine learning, and software as a medical device), and regulatory consulting space. Further, MAXIS bolsters the Avania depth across innovative technologies and multiple therapeutic areas.
 
Avania is a global full-service contract research organization focused on managing clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. 
 
MAXIS is a clinical market development company focused on maximizing the clinical, market and commercial success of medical technologies. MAXIS’ ability to design and implement flexible strategies, paired with its commitment to providing the comprehensive, long-term support make it uniquely suited to emerging medical technology companies. Its vast and varied startup experience enables the firm to create and adapt highly tailored, choreographed strategies to bring devices through development to the market. MAXIS has offices in San Jose, Calif.; and Frankfurt am Main, Germany, with additional operational staff across the regions.